Search results for "Pathway"

showing 10 items of 1685 documents

RNA Sequencing of Primary Cutaneous and Breast-Implant Associated Anaplastic Large Cell Lymphomas Reveals Infrequent Fusion Transcripts and Upregulat…

2021

Simple Summary Cutaneous and breast implant-associated anaplastic large-cell lymphomas are usually localized neoplasms with an indolent clinical course compared to systemic ALCL. However comparative analyses of the molecular features of these two entities have not yet been reported. We performed targeted RNA sequencing, which revealed that fusion transcripts, although infrequent, might represent additional pathogenetic events in both diseases. We also found that these entities display upregulation of the PI3K/Akt pathway and show enrichment in genes of the neurotrophin signaling pathway. These findings advance our knowledge regarding the pathobiology of cALCL and BI-ALCL and point to additi…

Cancer Researchalcl; fusion transcripts; ntrk signaling; pi3k/akt pathway; transcriptomeNeoplasms. Tumors. Oncology. Including cancer and carcinogensALCLfusion transcriptsArticleNTRK signalingOncologyPI3K/Akt pathwayhemic and lymphatic diseasesALCL; fusion transcripts; transcriptome; PI3K/Akt pathway; NTRK signalingfusion transcripttranscriptomeRC254-282Cancers; Volume 13; Issue 24; Pages: 6174
researchProduct

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.

2009

SummaryDysregulation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway occurs frequently in human cancer. PTEN tumor suppressor or PIK3CA oncogene mutations both direct PI3K-dependent tumorigenesis largely through activation of the AKT/PKB kinase. However, here we show through phosphoprotein profiling and functional genomic studies that many PIK3CA mutant cancer cell lines and human breast tumors exhibit only minimal AKT activation and a diminished reliance on AKT for anchorage-independent growth. Instead, these cells retain robust PDK1 activation and membrane localization and exhibit dependency on the PDK1 substrate SGK3. SGK3 undergoes PI3K- and PDK1-dependent activation in PI…

Cancer Researchanimal structuresCell SurvivalClass I Phosphatidylinositol 3-KinasesAKT1AKT2Breast NeoplasmsCELLCYCLEBiologyProtein Serine-Threonine Kinasesmedicine.disease_causeArticle03 medical and health sciencesPhosphatidylinositol 3-Kinases0302 clinical medicineCell Line TumorNeoplasmsmedicinePTENHumansProtein kinase BneoplasmsPI3K/AKT/mTOR pathway030304 developmental biology0303 health sciencesGene Expression ProfilingPTEN PhosphohydrolasePyruvate Dehydrogenase Acetyl-Transferring KinaseCell Biology3. Good healthEnzyme ActivationOncology030220 oncology & carcinogenesisCancer cellMutationCancer researchbiology.proteinFemaleSignal transductionCarcinogenesisProto-Oncogene Proteins c-aktSignal TransductionCancer cell
researchProduct

Abstract 1918: Gene characterization of lung-tumorspheres for their usage as an in vitro screening platform for testing new therapeutic strategies

2017

Abstract Background: Lung cancer features like treatment resistance or tumor relapse have been linked to cancer stem cells (CSCs), a population of cells with self-renewal properties, and the ability to grow forming tumorspheres in non-adherent conditions. The aim of this study was to isolate and characterize tumorspheres from lung cancer cell lines and tumor tissue from resectable non-small cell lung cancer (NSCLC) patients and to use them as an in vitro platform for drug screening. Methods: This study was performed on cells from seven NSCLC tumor samples and five cell lines (H1650, H1993, H1395, A549 and PC9) grown in monolayer and as spheroids. The expression of 60 genes, including CSC-ma…

Cancer ResearchbiologyCD44Notch signaling pathwayWnt signaling pathwayCancerVismodegibmedicine.diseaseVinorelbineBioinformaticsOncologyCancer stem cellmedicinebiology.proteinCancer researchLung cancermedicine.drugCancer Research
researchProduct

Abstract B154: A first-in-human trial of GDC-0068: A novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway i…

2011

Abstract GDC-0068 is a highly selective ATP-competitive small molecule that inhibits all three isoforms of Akt with IC50 values of 5 to 30 nM. GDC-0068 selectively inhibits cancer cells with activated Akt signaling (e.g. via PTEN loss or PIK3CA mutations). Patients with advanced solid tumors were treated with GDC-0068 using a 3+3 escalation design. GDC-0068 was dosed PO QD on a 21-day on, 7-day off schedule; endpoints included safety, pharmacokinetics (PK) and determination of pathway knockdown. Pharmacodynamics (PD) endpoints in surrogate tissue [platelet rich plasma (PRP)] were evaluated in all patients. In addition, at least two patients per cohort had pre- and on-treatment (day 15) tumo…

Cancer Researchbiologymedicine.diagnostic_testChemistryCancerPharmacologymedicine.diseaseOncologyPharmacokineticsPharmacodynamicsBiopsyCancer cellbiology.proteinmedicinePTENProtein kinase BPI3K/AKT/mTOR pathwayMolecular Cancer Therapeutics
researchProduct

Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma

2020

PI3K kinase has a prominent role in the B-cell receptor signaling. Copanlisib, a pan-PI3K inhibitor with predominant selectivity to PI3Kα and PI3Kδ, is Food and Drug Administration (FDA) approved for the treatment of patients with relapsed or refractory follicular lymphoma, and it is currently under clinical development in other indolent lymphomas including marginal zone lymphoma (MZL). However some patients might eventually relapse because of acquired resistance and so a better understanding of resistance mechanisms is needed. Thus we generated MZL cell lines resistant to copanlisib which could help to design improved therapies

Cancer Researchchemistry.chemical_compoundOncologychemistryResistance (ecology)Marginal zone lymphomaCancer researchlymphomaPI3K inhibitorBiologyPI3K/AKT/mTOR pathwayCopanlisibEuropean Journal of Cancer
researchProduct

Abstract LB-C21: CXCR7 expression is necessary for the maintenance of mesenchymal phenotype in acquired EGFR TKI resistance in NSCLC

2015

Abstract Activating EGFR mutations in non-small lung cancer (NSCLC) confer sensitivity to reversible EGFR tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib. Despite promising initial response, acquired resistance develops mediated by the emergence of the secondary T790M mutation or by focal amplification of MET. An epithelial-to-mesenchymal transition (EMT) is clinically linked to NSCLCs with acquired EGFR TKI resistance. The exact mechanisms of EGFR TKI resistance with EMT phenotype remain elusive; therefore, we have engineered EGFR-mutated NSCLC cell lines with mesenchymal phenotype by stably depleting E-Cadherin or by overexpressing Snail or chronically exposing the ce…

Cancer Researcheducation.field_of_studyPopulationMesenchymal stem cellCancerBiologymedicine.diseasePhenotyperespiratory tract diseasesT790MGefitinibOncologyCancer researchmedicineErlotinibeducationPI3K/AKT/mTOR pathwaymedicine.drugMolecular Cancer Therapeutics
researchProduct

Evolutionary convergence and nitrogen metabolism in Blattabacterium strain Bge, primary endosymbiont of the cockroach Blattella germanica.

2009

Bacterial endosymbionts of insects play a central role in upgrading the diet of their hosts. In certain cases, such as aphids and tsetse flies, endosymbionts complement the metabolic capacity of hosts living on nutrient-deficient diets, while the bacteria harbored by omnivorous carpenter ants are involved in nitrogen recycling. In this study, we describe the genome sequence and inferred metabolism of Blattabacterium strain Bge, the primary Flavobacteria endosymbiont of the omnivorous German cockroach Blattella germanica. Through comparative genomics with other insect endosymbionts and free-living Flavobacteria we reveal that Blattabacterium strain Bge shares the same distribution of functio…

Cancer Researchfood.ingredientlcsh:QH426-470NitrogenBlochmanniaZoologyCockroachesEvolution Molecular03 medical and health sciencesBlattabacteriumfoodSymbiosisEnterobacteriaceaePhylogeneticsAmmoniabiology.animalBotanyGeneticsAnimalsAmino AcidsSymbiosisMolecular BiologyGenetics (clinical)Ecology Evolution Behavior and SystematicsPhylogeny030304 developmental biology0303 health sciencesGerman cockroachCockroachbiologyPhylogenetic treeEvolutionary Biology/Evolutionary and Comparative Genetics030306 microbiologyAntsBacteroidetesfungiGenomicsbiochemical phenomena metabolism and nutritionbiology.organism_classificationGenetics and Genomics/Microbial Evolution and Genomicslcsh:GeneticsGenetics and Genomics/Genome ProjectsEvolutionary Biology/Microbial Evolution and GenomicsHost-Pathogen InteractionsBacteriaGenome BacterialMetabolic Networks and PathwaysResearch ArticlePLoS genetics
researchProduct

Abstract 1855: Role of mTOR inhibition in triple-negative breast cancer

2016

Abstract BACKGROUND: Triple-negative breast cancers (TNBC) represent the 10-17% of all diagnosed breast cancers (BC) and are characterized by the absence of ER/PgR expression, HER2 amplification and often show a basal-like phenotype. TNBC are often diagnosed in patients with BRCA1 germline mutation and unfortunately treatment options are still limited. The mTOR (Mammalian Target Of Rapamycin) pathway seems to play an important role in BC pathogenesis and it is possible to target this pathway by inhibitors such as rapamycin. In human BC cross talk between ER/PgR receptors signaling and the mTOR pathway is believed to be responsible for resistance to hormone therapy probably due to a down reg…

Cancer Researchmedicine.medical_specialtyCell growthmedicine.drug_classCancerBiologymedicine.diseaseEndocrinologyOncologyHormone receptorEstrogenInternal medicinemedicineCancer researchViability assayReceptorPI3K/AKT/mTOR pathwayTriple-negative breast cancerCancer Research
researchProduct

Geranylgeraniol - a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw.

2010

Bisphosphonate associated osteonecrosis of the jaw (BP-ONJ) is one of the main side effects of bisphosphonate therapy (BPT). To date, there is no effective therapy of the BP-ONJ. Nitrogen-containing bisphosphonates (N-BPs) are particularly able to inhibit pyrophosphate synthase (FPPS) in the mevalonate pathway (MVP). Consequent of decreased synthesis of the metabolite Geranylgeraniol (GGOH) is believed to largely account for the development of BP-ONJ. Negative effect of N-BPs could be shown, resulting in decreased viability and migration capacity of different cell types of hard and soft tissues such as osteoblasts, fibroblast und endothelial cells. Aim of our in vitro study was to demonstra…

Cancer Researchmedicine.medical_specialtyCell typeCellIn Vitro Techniqueschemistry.chemical_compoundGeranylgeraniolmedicineHumansFibroblastBisphosphonate-associated osteonecrosis of the jawMigration AssayOsteoblastsBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosisEndothelial CellsFibroblastsmedicine.diseaseSurgerymedicine.anatomical_structureOncologychemistryCancer researchMevalonate pathwayOral SurgeryDiterpenesbusinessWound healingJaw DiseasesOral oncology
researchProduct

mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA

2013

Abstract Vaccination with in vitro transcribed RNA encoding tumor antigens is an emerging approach in cancer immunotherapy. Attempting to further improve RNA vaccine efficacy, we have explored combining RNA with immunomodulators such as rapamycin. Rapamycin, the inhibitor of mTOR, was used originally for immunosuppression. Recent reports in mouse systems, however, suggest that mTOR inhibition may enhance the formation and differentiation of the memory CD8+ T-cell pool. Because memory T-cell formation is critical to the outcome of vaccination aproaches, we studied the impact of rapamycin on the in vivo primed RNA vaccine-induced immune response using the chicken ovalbumin-expressing B16 mela…

Cancer Researchmedicine.medical_treatmentImmunologyMelanoma ExperimentalCD8-Positive T-LymphocytesBiologyCancer VaccinesLymphocytes Tumor-InfiltratingImmune systemAntigenCancer immunotherapyAntigens NeoplasmIn vivomedicineAnimalsRNA NeoplasmPI3K/AKT/mTOR pathwaySirolimusVaccines SyntheticAntibiotics AntineoplasticTOR Serine-Threonine KinasesVaccinationRNACell DifferentiationCombined Modality TherapyMice Inbred C57BLVaccinationImmunologyCancer researchFemaleDrug Screening Assays AntitumorImmunologic MemoryCD8Cancer Immunology Research
researchProduct